FinEdge Labs
M

MDT

MDTUnverified
7 segments tracked|9 years of data|Annual (10-K)
Total Revenue
$54.4B4.4%
FY2025
Operating Segments
7
Active segments
Blended Margin
23.1%
Operating margin
Highest Margin
84.1%
Neuroscience Group
Segment Shift

Neuroscience Group has grown from 0.0% to 9.1% of total revenue since FY2015, with 84.1% operating margins. Meanwhile, Diabetes Group is the fastest growing at +10.7% YoY.

Segment Revenue Over Time

Revenue Mix

Segment Breakdown — FY2025

SegmentRevenueOp. IncomeMargin% of TotalYoY
Total Reportables$33.5B$00.0%61.6%+4.2%
Medical Surgical$6.5B$3.0B46.8%11.9%-0.2%
Cardiovascular$6.4B$4.8B75.1%11.8%+6.6%
Neuroscience Group$5.0B$4.2B84.1%9.1%+4.6%
Diabetes Group$2.8B$491M17.8%5.1%+10.7%
All Others$137M$00.0%0.3%-38.0%
Other$137M$49M35.8%0.3%+0.0%

Want more? Unlock the full analysis.

Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.

Get Started Free